GOQii has been on an overdrive to release solutions to monitor and track critical body vitals and manage chronic conditions. The mobile application and fitness bands are used in unison to screen and prevent diseases and disorders outside of the clinical setting. In a positive step towards quality assurance, GOQii has received medical device registration for the GOQii Smart Vital, Vital 3.0 and Vital ECG from the Central Drugs Standard Control Organization (CDSCO) under the Ministry of Health and Family Welfare, which is the national regulatory body for Indian pharmaceuticals and medical devices.

GOQii’s healthcare services are designed to monitor key vital parameters as a means to screen and prevent a range of diseases and disorders. The company integrates wearable technologies into its service ecosystem. The technology is intended for the qualitative detection of various health issues. The data generated from the fitness tracker can be shared in complete with personal health coaches and doctors digitally.

Wearable technology presents many compelling opportunities for improving healthcare. The use of wearables can enable healthcare consumers to analyze their biomarkers, receive digital coaching services and benefit on their insurance plans. Hundreds of thousands of patients with challenging lifestyle conditions like NAFLD, diabetes and hypertension, have already improved their outcomes from the company’s digital coaching services.

GOQii has partnered with KJ Somaiya Medical College and Research Centre for a seminal clinical study on the use of advanced wearable technology to provide doctors and medical staff with detailed health data on each COVID-19 patient under their care in real-time. The initial results of the study are promising, and an absolute focus has been laid upon the accuracy of the device.

In line with the Government of India’s push towards Atmanirbhar Bharat, GOQii is also making strides towards moving its manufacturing base to India. The company has already shifted some assembly activities to India. However, with the launch of several medical device manufacturing hubs across India and the incentives being offered in them - the company is hoping to move its complete manufacturing activities to India within the next 12 to 18 months.